Drugs made from antibodies are huge money-makers for some conditions — but they have gained little traction in infectious ...
Vantage Market Research’s recent analysis of the Global Monoclonal Antibodies Market finds that increasing incidence of cancer & other chronic diseases, rising Research and Development (R&D) ...
Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has approved its CAR T-cell therapy ...
Medicare's decision to deny coverage for the first new Alzheimer's treatment the FDA has approved in nearly 20 years will ...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V ...
Earlier this month, the American Society of Clinical Oncology (ASCO) hosted its annual meeting, drawing over 40,000 attendees from around the globe. The conference is one of the major events in the ...
The "Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use" report has been added to ResearchAndMarkets.com's offering.
The “Breast Cancer Monoclonal Antibodies Global Market Report 2022: By Product, By End-User” report has been added to ResearchAndMarkets.com’s offering. The global breast cancer monoclonal antibodies ...
Unfortunately, Omicron defeated most monoclonal ... stretched to the limit to meet ongoing demands for blood products.
A Senate Health, Education, Labor and Pensions Committee hearing demonstrated that there is no political will to continue to ...
Two monoclonal antibody therapies used to treat COVID-19 are now restricted for use throughout ... to have multiple options for COVID-19 treatment, the FDA-authorized treatments aren’t a ...
Cambridge-based Spirea Limited, which was created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has secured £2.4 million funding from UK and US investors. The investment ...